SecBot SecBot
8-K ·Filed Aug 10, 2026

SANA

Sana Biotechnology, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-342371
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The modest EPS miss is noise for a pre-revenue biotech; the stock will move on SC451 IND filing and SG293 clinical data catalysts expected within 6-9 months. Monitor for IND submission announcements and the EASD symposium on October 2 for UP421 data. The extended cash runway into mid-2027 removes near-term financing overhang.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs $93.8M ($0.39/share) in Q2 2025, driven by the absence of a prior-year $44.6M impairment. Non-GAAP net loss was $39.7M ($0.13/share), slightly wider than $38.9M ($0.16/share) last year and a 6.9% miss vs the $-0.12 consensus. Cash position improved to $160.5M from $138.4M at year-end 2025, bolstered by $93.3M in net equity proceeds from ATM sales and the Mayo Clinic investment, extending the cash runway into mid-2027. The stock will trade on pipeline catalysts, SC451 IND filing and SG293 first-in-human data expected within 6-9 months, rather than the modest EPS miss, which is a mechanical artifact of share-count dilution for this pre-revenue biotech.

Key Financial Metrics

EPS
−$0.13
est −$0.12 · -8.3%
Rating
in line

Key Facts

  • Q2 2026 GAAP net loss $63.6M ($0.22/share) vs $93.8M ($0.39/share) in Q2 2025; prior year included $44.6M impairment
  • Non-GAAP net loss $39.7M ($0.13/share) vs consensus $-0.12, a 6.9% miss
  • Cash, cash equivalents, and marketable securities $160.5M as of June 30, 2026, up from $138.4M at Dec 31, 2025
  • Raised $93.3M net proceeds from ATM stock sales and Mayo Clinic equity investment in Q2 2026
  • Expected cash runway into mid-2027
  • SC451 (type 1 diabetes) IND and Phase 1/2 trial start expected as early as this year; SG293 (non-Hodgkin lymphoma) first-in-human data expected as early as this year
  • NEJM publication of 14-month UP421 data showing islet cell survival without immunosuppression
  • Mayo Clinic strategic collaboration advancing SC451 development
  • Weighted-average shares outstanding 295.7M in Q2 2026 vs 238.4M in Q2 2025, 24% dilution

Financial Impact

Q2 2026 GAAP net loss $63.6M; Non-GAAP net loss $39.7M; cash burn $69.3M in H1 2026; $93.3M equity raised

net losscash positiondilution

Risk Factors

  • Clinical trial delays or negative data for SC451 or SG293
  • Further dilution from ATM sales or additional equity financing
  • Significant non-cash contingent consideration and success payment liabilities ($175.3M) create earnings volatility

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342371
Document: sana-20260810.htm0001193125-26-342371
Document: 0001193125-26-342371-index-headers.html0001193125-26-342371
Document: 0001193125-26-342371-index.html0001193125-26-342371
Document: 0001193125-26-342371.txt0001193125-26-342371
8-K Data (Synthetic)0001193125-26-342371

Track record

12 reports on SANA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 Viewing No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026